IRVING, Texas and ABBOTT PARK, Ill., Nov. 20, 2010 /PRNewswire-FirstCall/ -- Reata Pharmaceuticals and Abbott (NYSE: ABT) today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and